Robert S. Landsman

Array ( [id] => 18667561 [patent_doc_number] => 11774452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Antibodies against carcinoembryonic antigens [patent_app_type] => utility [patent_app_number] => 18/164206 [patent_app_country] => US [patent_app_date] => 2023-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 14056 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511402 [patent_doc_number] => 20230227551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/162447 [patent_app_country] => US [patent_app_date] => 2023-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18726265 [patent_doc_number] => 20230340533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/158852 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19870384 [patent_doc_number] => 12263223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-01 [patent_title] => Method of treating diseases of the kidney and urinary tract by administering a peptide-linked therapeutic agent [patent_app_type] => utility [patent_app_number] => 18/095753 [patent_app_country] => US [patent_app_date] => 2023-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 61 [patent_no_of_words] => 17979 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18095753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701509 [patent_doc_number] => 12195518 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof [patent_app_type] => utility [patent_app_number] => 18/091361 [patent_app_country] => US [patent_app_date] => 2022-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 13 [patent_no_of_words] => 12252 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18346540 [patent_doc_number] => 20230134650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => METHODS OF TREATING CANCER WITH INTERFERON WHEREIN THE CANCER CELLS ARE HLA NEGATIVE OR HAVE REDUCED HLA EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/146773 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10086 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18146773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707673 [patent_doc_number] => 20230330253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 18.2 [patent_app_type] => utility [patent_app_number] => 18/065371 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187098 [patent_doc_number] => 12398203 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Method for producing bispecific antibodies comprising a Y436A Fc-region mutation for improved protein A-binding [patent_app_type] => utility [patent_app_number] => 18/079307 [patent_app_country] => US [patent_app_date] => 2022-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 41375 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675159 [patent_doc_number] => 20230312747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Compositions and Methods for Treating Cancer [patent_app_type] => utility [patent_app_number] => 18/062265 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861967 [patent_doc_number] => 20230416403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/062473 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20882290 [patent_doc_number] => 12698321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Antibodies which have specificity to a sarbecovirus spike protein receptor-binding domain and methods of use thereof for treating a coronavirus infection [patent_app_type] => utility [patent_app_number] => 18/060814 [patent_app_country] => US [patent_app_date] => 2022-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 123 [patent_no_of_words] => 42553 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675101 [patent_doc_number] => 20230312678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => ARTIFICIAL SYNAPSES [patent_app_type] => utility [patent_app_number] => 18/056029 [patent_app_country] => US [patent_app_date] => 2022-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468890 [patent_doc_number] => 20230203173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR IGM ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/055340 [patent_app_country] => US [patent_app_date] => 2022-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436075 [patent_doc_number] => 20230183369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => TRANSFERRIN RECEPTOR (TFR)-SELECTIVE BINDING PEPTIDES CAPABLE OF CROSSING THE BLOOD BRAIN BARRIER AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/050234 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18319896 [patent_doc_number] => 20230118024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => ANTI-HLA-DQ2.5 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/974949 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17974949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451596 [patent_doc_number] => 20230192874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/045592 [patent_app_country] => US [patent_app_date] => 2022-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20757036 [patent_doc_number] => 12649795 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies and method of use thereof to treat thyroid-associated opthamology [patent_app_type] => utility [patent_app_number] => 17/938674 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 0 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701370 [patent_doc_number] => 11787869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness [patent_app_type] => utility [patent_app_number] => 17/936483 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 34415 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701370 [patent_doc_number] => 11787869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness [patent_app_type] => utility [patent_app_number] => 17/936483 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 34415 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701370 [patent_doc_number] => 11787869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness [patent_app_type] => utility [patent_app_number] => 17/936483 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 34415 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936483 [rel_patent_id] =>[rel_patent_doc_number] =>)